DOCS enters its fiscal Q4 2026 earnings report on May 13 carrying a heavy short position and a stock that has already been savaged — creating a setup where the bar may be low but the crowd is far from convinced.
Short sellers hold 10.5% of the free float, a position that has climbed roughly 16% over the past month, though it has edged back slightly this week. With days-to-cover near five, this is not a position bears can exit quickly. Yet borrow conditions tell a different story: cost-to-borrow has eased more than 30% over the past month to just 0.37%, and availability has widened considerably — the lending pool is loose, and short positioning remains comfortable and uncrowded. The ORTEX short score of 49.8 confirms the picture: elevated but not extreme.
Options positioning is notably calm heading into the print. The put/call ratio of 0.68 runs only modestly above its 20-day average of 0.64, roughly 0.8 standard deviations — well within normal range. Calls continue to dominate the options market, suggesting that options traders are not bracing for a major decline. The broader price backdrop is more complicated: the stock has rebounded 15% over the past month to $25.98 after collapsing more than 41% year-to-date, clawing back some ground from lows that followed a brutal February earnings reaction of -21% in a single session and -30% over the subsequent five days.
That February crash shapes how analysts and investors are reading the May print. The bear case centres on policy headwinds facing pharma clients, with Q4 guidance pointing to only ~4% revenue growth and net revenue retention for the top 20 customers falling to 112% — a deceleration that spooked the Street. Truist downgraded to Hold in April, cutting its target to $29. Goldman Sachs and Evercore ISI also lowered targets in April, with Evercore moving to In-Line from Outperform. The consensus has shifted: 11 buys remain, but 7 holds have accumulated, and the mean price target of $37.77 implies 45% upside from current levels — a wide gap that reflects genuine disagreement rather than Street conviction. Bulls point to a Q3 beat on revenues ($185.1 million, up 10% year-over-year), record engagement metrics, and strong momentum with the top 20 clients, arguing Doximity's platform has durable pricing power that the current multiple does not credit. Insiders have been net sellers across the board in recent months — the Acting CFO, CEO, and a board director all trimmed — though the trades were modest in size and low in significance, more consistent with routine plan selling than strategic distribution.
The May 13 report tests whether the company's Q4 revenue trajectory and any update on pharma client budgeting can close the gap between a 45% implied upside and a stock that the market has repriced sharply lower — or whether the bear case on policy headwinds is still running.
See the live data behind this article on ORTEX.
Open DOCS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
